The Novavax vaccine has reported an efficacy of 90% i …

The Covid-19 vaccine Novavax is more than 90% effective, even against new variants of the coronavirus, confirmed Monday the American laboratory after a large-scale study in two countries.

The vaccine “has demonstrated 100% protection against moderate and severe diseases, and an overall effectiveness of 90.4% “, The company said in a statement, adding that “the study was conducted among 29,960 participants at 119 sites in the United States and Mexico to assess efficacy, safety and immunogenicity.”

The Maryland-based company said it plans to seek regulatory approval by the third quarter of 2021. After obtaining it, plans to manufacture 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the year.

“Today, Novavax takes one more step towards meeting the critical and persistent global public health need for additional COVID-19 vaccines,” said Stanley Erck, CEO of the company.

“Novavax continues to work with a sense of urgency to complete our regulatory clearance requests and offer this vaccine, cbuilt on a well-known and proven platform, to a world that is still in dire need of vaccines. ”

While most smart countries are making progress in immunizing their populations, there is concern that many more countries are falling behind in the global immunization campaign.

Immunization rates in the world’s poorest countries are far behind those of the industrialized powers of the G7 and other rich countries. Considering the doses administered so far, the imbalance between the G7 and low-income countries, as defined by the World Bank, is 73 to one.

Unlike some vaccines already applied, Novavax, officially known as NVX-CoV2373, does not need to be stored at ultra-low temperatures.

The company said she was “stored and stable between 2 ° C and 8 ° C, enabling the use of existing channels in the vaccine supply chain for distribution. “

This means, in theory at least, that these vaccines should be more easily transported and administered in countries with less developed health infrastructures.